

6. The correction of the paragraph No. [0047] of the page No. 29 of said specification:
add the currently presented " in step five " between the first word, level, and the second word, is, of the third line of said paragraph No. [0047].
7. The correction of the paragraph No. [0054] of the page No. 31 of said specification:
previously original " 85 s^{-1} " in the fourth line of said paragraph No. [0054] to correct to currently presented " 85 per minute ".
8. The correction of the line No. 120 of the claim 4 of the page No. 42 of said claims:
add the currently presented " wherein " between the sixth word, 1, and the seventh word, determining, in said line No. 120 of said claim 4.
9. The correction of the line No. 174 of the claim 6 of the page No. 44 of said claims:
previously original " 72 s^{-1} " in said line No. 174 of said claim 6 to correct to currently presented " 72 per minute ".
10. The correction of the line No. 339 of the claim 17 of the page No. 52 of said claims:
add the currently presented " in claim 12 " between the fifth word, level, and the sixth word, is, in said line No. 339.

Please find enclosed both previously original and correctly presented paragraphs of the specification and claims and enclosed a copy of the receipt dated 08/06/2004 from the United States Patent and Trademark Office.

I appreciate it if above-mentioned said incorrect words and symbols can be corrected soon.

Please contact me at phone No.: (774) 239-3884, fax No.: (508) 831-0592 or e-mail: xwang3wco@yahoo.com if there is any question involving above-mentioned matter.

Thank you.

Sincerely,

Xingfa Wang

Xing Fa Wang, Ph.D.
(Customer No.: 35673)

Encl.: Both previously original and corrected presented paragraphs of the specification and claims of 8 pages; a copy of the receipt dated 08/068/2004 of 1 page. The Express Mail Label No.: ER 855038855 US indicates on the tope of enclosed every page.



Both Previously Original and Corrected Presented Paragraphs of Said Specification and Claims:

1. The correction of the Heading of the page No. 3 of said specification:

previously original heading of said page No. 3:

REFEENCES CITED

to correct to currently presented heading of said page No. 3:

REFERENCES CITED

2. The correction of the Heading of the page No. 10 of said specification:

previously said original heading of said page No. 10:

BRIEF DISCRIPTION OF THE DRAWING

to correct to currently presented heading of said page No. 10:

BRIEF DESCRIPTION OF THE DRAWING

3. The correction of the paragraph No. [0023] of the page No. 16 of said specification:

previously original symbol “ ; ” at the end of said paragraph No. [0023]:

[0023] Since the previous eddy is proportional to the average velocity of the fluid in a circular tube, the eddy has the form

$$v = H_b u \quad (D)$$

where v = the eddy and H_b is a parameter that is independent of u . Substituting (C) into (D) yields:

$$v = H_a H_b p a^2; \quad (E)$$

to correct to currently presented symbol “.” at the end of said [0023] paragraph:

[0023] Since the previous eddy is proportional to the average velocity of the fluid in a circular tube, the eddy has the form

$$v = H_b u \quad (D)$$

where v = the eddy and H_b is a parameter that is independent of u . Substituting (C) into (D) yields:

$$v = H_a H_b p a^2. \quad (E)$$

4. The correction of the paragraph No. [0044] of the page No. 28 of said specification:

previously original symbol “;” at the end of said paragraph No. [0044]:

[0044] Step seven: selecting a greater flux between the LDL mass transfer flux and the monocyte mass transfer flux so as to result in this greater flux as a primary

cause in the disease, said method comprising the steps of:

selecting the LDL mass transfer flux as a primary cause in the disease when R_1 in Step 3.1 $\geq R_2$ in Step 3.3; or

selecting the monocyte mass transfer flux as a primary cause in the disease when R_1 in Step 3.1 $< R_2$ in Step 3.3;

to correct to currently presented symbol “.” at the end of said [0044] paragraph:

[0044] Step seven: selecting a greater flux between the LDL mass transfer flux and the monocyte mass transfer flux so as to result in this greater flux as a primary cause in the disease, said method comprising the steps of:

selecting the LDL mass transfer flux as a primary cause in the disease when R_1 in Step 3.1 $\geq R_2$ in Step 3.3; or

selecting the monocyte mass transfer flux as a primary cause in the disease when R_1 in Step 3.1 $< R_2$ in Step 3.3.

5. The correction of the paragraph No. [0045] of the page No. 28-29 of said specification:

previously original symbol “;” at the end of said paragraph No. [0045]:

[0045] Step eight: Selecting an greater level between a measured value of the LDL concentration parameter in Step 3.1 and a measured value of the CRP concentration parameter in Step 3.2 so as to result in this greater level as a secondary therapy target of the disease, said method comprising the steps of:

selecting the LDL concentration level in serum as a secondary therapy target of the disease when R_1 in Step 3.1 $\geq R_2$ in Step 3.3; or
selecting the CRP concentration level in blood plasma as a secondary therapy target of the disease when R_1 in Step 3.1 $< R_2$ in Step 3.3;

to correct to currently presented symbol “.” at the end of said [0045] paragraph:

[0045] Step eight: Selecting an greater level between a measured value of the LDL concentration parameter in Step 3.1 and a measured value of the CRP concentration parameter in Step 3.2 so as to result in this greater level as a secondary therapy target of the disease, said method comprising the steps of:

selecting the LDL concentration level in serum as a secondary therapy target of the disease when R_1 in Step 3.1 $\geq R_2$ in Step 3.3; or
selecting the CRP concentration level in blood plasma as a secondary therapy target of the disease when R_1 in Step 3.1 $< R_2$ in Step 3.3.

6. The correction of the paragraph No. [0047] of the page No. 29 of said specification:

previously original paragraph No. [0047] of said page No. 29:

[0047] Step ten: Repeating the method in Step three through the method in Step nine until the disease risk level is reduced to a normal level for the individual who requires the therapy to prevent or to treat atherosclerosis-related CHD or stroke.

to correct to currently presented added " in step five " between the first word, level, and the second word, is, of the third line of said [0047] paragraph:

[0047] Step ten: Repeating the method in Step three through the method in Step nine until the disease risk level in step five is reduced to a normal level for the individual who requires the therapy to prevent or to treat atherosclerosis-related CHD or stroke.

7. The correction of the paragraph No. [0054] of the page No. 31 of said specification:

previously original " 85 s^{-1} " in the fourth line of said [0054] paragraph:

[0054] Example 2. An individual having a measured value of the LDL concentration in serum of 110 mg/dL, a measured value of blood systolic pressure of 195 mmHg, a measured heart rate of 85 s^{-1} and a measured value of the CRP level in blood plasma of 1.2 mg/L.